Project Grant HT94252410836
Award Date 8/1/24
Completion Date 7/31/27
Dollars Obligated $769K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Similar Awards
- The Defense Health Agency awarded a $464,261 project grant to The Royal Institution For The Advancement Of Learning, a private, non-profit educational institution in Montreal, Canada, to develop the next generation of prognostic tools for localized clear cell renal cell carcinoma. The grant, awarded under the Military Medical Research and Development (CFDA 12.420) program, will fund research to integrate genomic, clinical, and pathological features to create advanced prognostic tools for this...
- The Defense Health Agency awarded a $416,115 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Research Institute Of The Mcgill University Health Centre. The grant, awarded on August 15, 2024, will fund the development of next-generation prognostic tools for localized clear cell renal cell carcinoma through the integration of genomic, clinical, and pathological features. The award has a performance period ending on August 14, 2026. The Research...
- The Department of the Army Medical Command awarded a $116,692 Project Grant to the Royal Institution For The Advancement Of Learning / McGill under the Military Medical Research and Development program. The grant will fund a research project titled "UNDERSTANDING PHYSICAL DETERMINANTS OF HETEROGENEITY IN RENAL CANCER CARCINOMA" from July 15, 2021 to July 14, 2023. The project will be performed at 2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada. Through this funding, the awardee will...
- The Department of the Army Medical Command awarded a $390,033 Project Grant to Mount Sinai Hospital in Ottawa, Ontario, Canada to identify novel immune evasion tumor immune networks as targets for clear cell renal cell carcinoma immunotherapy. The grant was awarded on August 15, 2022 under the Military Medical Research and Development program (CFDA 12.420) and will support research activities through August 14, 2025. The Military Medical Research and Development program aims to transform...
- The Project Grant award of $1,387,727.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support the "Integrated Immunomodulatory Analysis of LAG3 Inhibition in Renal Cell Carcinoma" research project conducted by the Sloan-Kettering Institute for Cancer Research in New York, NY. The award period runs from September 1, 2025 to August 31, 2029. The research aims to advance the scientific understanding and develop innovative diagnostic...
- This $1,044,720 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research by Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to develop targeting kits using mono- and bi-paratopic antibody drug conjugates for chromophobe renal cell carcinoma. The award has an initial performance period from August 1, 2024 to July 31, 2027. The objective is to advance innovative therapeutic...
- The Department of the Army Medical Command awarded a $475,457 Project Grant to the Institute of Cancer Research: Royal Cancer Hospital in the United Kingdom. The grant is part of the Military Medical Research and Development program (CFDA 12.420) and will fund research characterizing biomarkers of growth and progression in small renal masses from September 30, 2022 to September 29, 2025. Through this award, the grantee will investigate medical solutions for the battlefield by transforming...
- The Department of the Army Medical Command awarded Duke University a $1,932,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) for the period of September 1, 2022 through August 31, 2025. The grant funds research to define cellular and genetic factors for renal cell carcinoma subtypes. Through this award, Duke University researchers will investigate medical solutions for kidney cancer on the cellular and genetic levels to advance understanding,...
- The federal Project Grant award for "TARGETING P2X7 RECEPTOR IN RENAL CELL CARCINOMA", totaling $1,269,000.00, was awarded to The Institute For Cancer Research, a non-profit subsidiary of Temple University, by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports biomedical research focused on developing new treatments for kidney cancer, a key health concern for military service members and veterans. The Institute For...
- The Defense Health Agency awarded a $1,023,225 Project Grant under the Military Medical Research and Development program (CFDA# 12.420) to The Cleveland Clinic Foundation. The grant funds research to investigate the therapeutic relevance of targeting the anti-apoptotic Bcl-xL protein in kidney cancer. A sub-award to Harvard T.H. Chan School of Public Health will perform BH3 profiling to compare apoptotic responses in renal cell carcinomas under varied conditions, including treatment with BH3...